Dr. John Cush RheumNow
1 week 4 days ago
JAMA Surgery analysis showed that between 2022-2024 bariatric surgery fell 34.1%, While GLP-1 use rose more than 140% over the same period. (SELECT trial showed semaglutide reduced major adverse cardiovascular events by 20% in overweight or obese adults without diabetes.) https://t.co/s3NRFY2R5w
Dr. John Cush RheumNow
1 week 4 days ago
TriNetX retrospective EHR study showed VTE in #RA not incr by taking JAKi. Pts undergoing THA/TKA Rx w/ JAKi (n 284) vs TNFi (n 288). VTE- 17 JAKi (6%) vs 11 TNFi (3.8%)- nonsignif incr (RR 1.57) https://t.co/OM5ipieQtr https://t.co/ng8b9EkWmT
Dr. John Cush RheumNow
1 week 4 days ago
Together PsA 52 wk data (n 271): ACR50 plus >10% wt loss - 39.2% w/ Taltz & Zepbound vs 1.7% w/ Taltz alone. Together PsO trial results (n 274): PASI100 plus >10% wt loss - 30.6% w/ Taltz & Zepbound vs 4.4% w/ Taltz alone. https://t.co/27TBZyL8l1 https://t.co/VdQJALdoJt
Dr. John Cush RheumNow
1 week 4 days ago
Waist size matters! Using NHANES data (1999-2018) the weight-adjusted waist index (WWI) calculated on 5582 CKD pts. WWI was signif assoc w/ all-cause mortality (adj HR 1.17) & CV (1.24); these assoc partially mediated by NLR (inflammation) ~6.6%, showing both central adiposity https://t.co/kNf4nqiD2a
Weight loss with lifestyle changes alone is difficult to sustain for most people. One reason for this is the weight loss associated endocrine milieu, which can decrease energy expenditure and increase the drive to eat. Therefore, we frequently use medications and/or bariatric surgery.
Dr. John Cush RheumNow
1 week 5 days ago
True or False: A meta-analysis of hidradenitis suppurativa patients showed IL-17 inhibitors significantly increased IBD risk compared to placebo.
See if you got it right in this week's RheumIQ quiz at https://t.co/UaXqHKWizt.
Dr. John Cush RheumNow
1 week 5 days ago
Sobi Receives US FDA Fast Track Designation for pacritinib in VEXAS Syndrome. Pacritinib (Vonjo) is a kinase inhibitor (JAK2, FLT3) that is approved to treat adults with intermediate or high-risk myelofibrosis https://t.co/V7duJPyJpG https://t.co/Dn5DgeaX7N
Dr. John Cush RheumNow
1 week 6 days ago
RheumIQ: In axial spondyloarthritis, obesity reduces TNF inhibitor responses by how much?
Test your knowledge at https://t.co/UaXqHKWizt.
Dr. John Cush RheumNow
1 week 6 days ago
Osteoarthritis, Obesity and GLP-1s
https://t.co/SGnWksQBpT https://t.co/ILP3weScxh
Dr. John Cush RheumNow
1 week 6 days ago
Leeds study of 44 patients idiopathic inflamm myopathy (IIM) pts Rx w/ rituximab showed a 70% response 4-6 mos post RTX. Responders had higher TIS (50·0 vs 17·5). Using highly sensitive flow cytometry, @ 2 wks responders had lower #s memory B cells & Plasmablasts. Is there a role https://t.co/JDvVZ1KEIY
Dr. John Cush RheumNow
1 week 6 days ago
Music and Pain Relief
A new scoping review in Pain Reports by Bradt et al., examines the effect of MBIs on pain management. While its efficacy is well established, how or why music relieves pain has never been fully explained. This systematic review is based on 663 records and https://t.co/0FJgzWSoOB
Dr. John Cush RheumNow
1 week 6 days ago
EBR Journal Club: Dapirolizumab Pegol in SLE (PHOENYCS GO)
The EBR Journal Club Companion applies my adapted version of the JAMA approach to critical appraisal to an important RCT in rheumatology. Each review covers four domains: Does this apply to my patients? What is the risk https://t.co/Pi45T99oJm
Dr. John Cush RheumNow
1 week 6 days ago
True or False: In a Leeds study of idiopathic inflammatory myopathy patients treated with rituximab, responders had lower memory B cells and plasmablasts at 2 weeks.
See if you got it right in this week's RheumIQ quiz at https://t.co/UaXqHKWizt. https://t.co/zRJOMeLn8M
Dr. John Cush RheumNow
2 weeks ago
QD Clinic: Weight Loss Changed the Course of RA
Dr. Bella Mehta, New York, presents this case which highlights that obesity may be a target for disease modification in rheumatoid arthritis, as part of RheumNow's "The Obesity Imperative" campaign, presented in September 2026. https://t.co/KNNS0cHmA4
